F-18 FDG uptake due to acinetobacter infection causing misinterpretation of treatment response in a lymphoma patient

Clinical Nuclear Medicine

Volumn 32, Issue 6, 2007, Pages 471-473

  Yildiz, Ramazan ^a   Coskun, Ugur ^a   Kapucu, Ozlem ^a   Kaya, Ali Osman ^a   Akdemir, Umit Ozgur ^a   Benekli, Mustafa ^a   Buyukberber, Suleyman ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Acinetobacter infection; Lymphoma; Positron emission tomography; Pulmonary lesions

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; VINCRISTINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; B CELL LYMPHOMA; BACTERIAL INFECTION; BACTERIUM CULTURE; BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CERVICAL LYMPH NODE; DRUG UPTAKE; FEBRILE NEUTROPENIA; FEMALE; FIBEROPTIC BRONCHOSCOPY; HUMAN; HUMAN TISSUE; MONITORING; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

ACINETOBACTER INFECTIONS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRONCHOSCOPY; CYCLOPHOSPHAMIDE; DIAGNOSIS, DIFFERENTIAL; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG DISEASES; LYMPHOMA, B-CELL; MIDDLE AGED; PREDNISONE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; VINCRISTINE;

EID: 34249111402     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318053ed08     Document Type: Article

References (15)

1. Mascarenhas NB, Lam D, Lynch GR, et al. PET imaging of cerebral and pulmonary Nocardia infection. Clin Nucl Med. 2006;31:131-133.
2. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875-3876.
3. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464-4471.
4. Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. Clin Nucl Med. 1996;21:941-949.
5. Xiu Y, Yu JQ, Cheng E, et al. Sarcoidosis demonstrated by FDG PET imaging with negative findings on gallium scintigraphy. Clin Nucl Med. 2005;30:193-195.
6. Mackie GC, Pohlen JM. Mediastinal histoplasmosis: F-18 FDG PET and CT findings simulating malignant disease. Clin Nucl Med. 2005;30:633-635.
7. Shie P, Farukhi I, Hughes RS, et al. Round pneumonia mimicking pulmonary malignancy on F-18 FDG PET/CT. Clin Nucl Med. 2007;32:55-56.
8. Win Z, Todd J, Al-Nahhas A. FDG-PET imaging in Pneumocystis carinii pneumonia. Clin Nucl Med. 2005;30:690-691.
9. Yen RF, Chen ML, Liu FY, et al. False-positive 2-[F-18]-fluoro-2-deoxy- D-glucose positron emission tomography studies for evaluation of pulmonary abnormalities. J Formos Med Assoc. 1998;97:642-645.
10. Hsu CH, Lee CM, Wang FC, et al. F-18 fluorodeoxyglucose positron emission tomography in pulmonary cryptococcoma. Clin Nucl Med. 2003;28:791-793.
11. Mascarenhas NB, Lam D, Lynch GR, et al. PET imaging of cerebral and pulmonary nocardia infection. Clin Nucl Med. 2006;31:131-133.
12. Goethals I, Smeets P, De Winter O, et al. Focally enhanced F-18 fluorodeoxyglucose (FDG) uptake in incidentally detected pulmonary embolism on PET/CT scanning. Clin Nucl Med. 2006;31:497-498.
13. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-314.
14. Pandit N, Yeung HW. F-18 FDG uptake in pulmonary lymphangioleiomyomatosis. Clin Nucl Med. 2001;26:1050-1051.
15. Cura M, Smoak W, Dala R. Pulmonary meningioma: false-positive positron emission tomography for malignant pulmonary nodules. Clin Nucl Med. 2002;27:701-704.